BioLineRx to reacquire rights to schizophrenia drug from Cypress
This article was originally published in Scrip
Executive Summary
BioLineRx is to reacquire the rights to its schizophrenia drug candidate, BL-1020, from Cypress Bioscience and is planning to start a Phase II/III clinical trial investigating the product's effect on cognition in June, it said.